Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats

Thrombosis Research

Volumn 133, Issue 5, 2014, Pages 900-907

  Herzog, Eva ^a   Harris, Stephen ^b   Henson, Claire ^b   McEwen, Andrew ^b   Schenk, Sabrina ^a   Nolte, Marc W ^a   Pragst, Ingo ^a   Dickneite, Gerhard ^a   Schulte, Stefan ^a   Zollner, Sabine ^a  

^a CSL BEHRING GMBH   (Germany)

^b Quotient Bioresearch Ltd   (United Kingdom)

Author keywords

Albumin fusion; Biodistribution; Coagulation factor IX; Pharmacokinetics; Recombinant factor IX

Indexed keywords

ALBUMINOID; BLOOD CLOTTING FACTOR 9; HYBRID PROTEIN;

ANIMAL; HUMAN; KNEE; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ALBUMINS; ANIMALS; FACTOR IX; HUMANS; KNEE JOINT; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 84898821672     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.02.010     Document Type: Article

References (39)

1. L.A. Suzuki, and A.R. Thompson Factor IX antigen by a rapid staphylococcal protein A-membrane binding radioimmunoassay: results in haemophilia B patients and carriers and in fetal samples Br J Haematol 50 1982 673 682
2. B. Osterud, B.N. Bouma, and J.H. Griffin Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI J Biol Chem 253 1978 5946 5951
3. C.M. Jackson, and Y. Nemerson Blood coagulation Annu Rev Biochem 49 1980 765 811
4. I.M. Nilsson, E. Berntorp, T. Lofqvist, and H. Pettersson Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B J Intern Med 232 1992 25 32
5. S. Björkman, A.D. Shapiro, and E. Berntorp Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis Haemophilia 7 2001 133 139
6. B.M. Ewenstein, J.H. Joist, A.D. Shapiro, T.C. Hofstra, C.A. Leissinger, and S.V. Seremetis et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B Transfusion 42 2002 190 197
7. H.J. Metzner, T. Weimer, U. Kronthaler, W. Lang, and S. Schulte Genetic fusion to albumin improves the pharmacokinetic properties of factor IX Thromb Haemost 102 2009 634 644
8. M.W. Nolte, T.C. Nichols, J. Mueller-Cohrs, E.P. Merricks, I. Pragst, and S. Zollner et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs J Thromb Haemost 10 2012 1591 1599
9. S. Schulte Half-life extension through albumin fusion technologies Thromb Res 124 Suppl. 2 2009 S6 S8
10. G.H. Müller Protein labeling with 3H-NSP (N-succinimidyl-[2,3,-3H] propionate) J Cell Sci 43 1980 319 328
11. S. Ullberg Studies on the distribution and fate of 35S-labelled benzylpenicillin in the body Acta Radiol Suppl. 118 1954 1 110
12. R.J. Kaufman, L.C. Wasley, B.C. Furie, B. Furie, and C.B. Shoemaker Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells J Biol Chem 261 1986 9622 9628
13. BeneFIX [(Coagulation Factor IX (Recombinant)] Available at: http://labeling.pfizer.com/showlabeling.aspx?id=492 [Accessed October 24, 2013]
14. C.-H. Chang, T.-K. Chou, C.-Y. Yang, T.-J. Chang, Y.-H. Wu, and T.-W. Lee Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats In Vivo 22 2008 693 698
15. H.E. Fuchs, H.G. Trapp, M.J. Griffith, H.R. Roberts, and S.V. Pizzo Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors J Clin Invest 73 1984 1696 1703
16. O.D. Holton III, C.D. Black, R.J. Parker, D.G. Covell, J. Barbet, and S.M. Sieber et al. Biodistribution of monoclonal IgG1, F(ab0)2, and Fab0 in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies J Immunol 139 1987 3041 3049
17. J.E. Schnitzer, and J. Bravo High affinity binding, endocytosis, and degradation of conformationally modified albumins - potential role of gp30 and gp18 as novel scavenger receptors J Biol Chem 268 1993 7562 7570
18. S.K. Moestrup, J. Gliemann, and G. Pallesen Distribution of the alpha 2-macroglobin receptor/low density lipoprotein receptor-related protein in human tissues Cell Tissue Res 259 1992 375 382
19. P.J. Lenting, J.G. Neels, B.M.M. van den Berg, B.M.M. van den Berg, P.F.M. Clijsters, D.W.E. Meijerman, and H. Pannekoek et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein J Biol Chem 274 1999 31305 31311
20. R. Gopalakrishnan, U. Hedner, S. Ghosh, R.C. Najak, T.C. Allen, and U.R. Pendurthi et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa) Thromb Haemost 8 2010 301 310
21. W.F. Cheung, N. Hamaguchi, K.J. Smith, and D.W. Stafford Identification of the endothelial cell binding site for factor IX Proc Natl Acad Sci U S A 92 1992 11068 11073
22. A.S. Wolberg, D.W. Stafford, and D.A. Erie Human factor IX binds to specific sites on the collagenous domain of collagen IV J Biol Chem 272 1997 16717 16720
23. T. Gui, H.F. Lin, D.Y. Jin, M. Hoffman, D.L. Straight, and H.R. Roberts et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo Blood 100 2002 153 158
24. M. Lindsay Characterization of post-translational modifications and resulting structure/function relationships of recombinant human factor IX produced in the milk of transgenic pigs Chapter 5. Dissertation 2004 Virginia Polytechnic Institute and State University Blacksburg, VA
25. C. Chaudhury, S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Pearl, and D.C. Roopenian et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan J Exp Med 197 2003 315 322
26. C.L. Anderson, C. Chaudhury, J. Kim, C.L. Bronson, M.A. Wani, and S. Mohanty Perspective - FcRn transports albumin: relevance to immunology and medicine Trends Immunol 27 2006 343 348
27. J. Kim, C.L. Bronson, W.L. Hayton, M.D. Radmacher, D.C. Roopenian, and J.M. Robinson et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces Am J Physiol Gastrointest Liver Physiol 290 2005 G352 G360
28. T.T. Kuo, K. Baker, M. Yoshida, S.W. Qiao, V.G. Aveson, and W.I. Lencer et al. Neonatal Fc receptor: from immunity to therapeutics J Clin Immunol 30 2010 777 789
29. D.C. Roopenian, and V.Z. Sun Clinical ramifications of the MHC family Fc receptor FcRn J Clin Immunol 30 2010 790 797
30. S.S. Siddiqui, Z.K. Siddiqui, and A.B. Malik Albumin endocytosis in endothelial cells induces TGF-beta receptor II signaling Am J Physiol Lung Cell Mol Physiol 286 2004 L1016 L1026
31. N. Ghinea, M. Eskenasy, M. Simionescu, and N. Simionescu Endothelial albumin binding proteins are membrane-associated components exposed on the cell surface J Biol Chem 264 1989 4755 4758
32. J.E. Schnitzer, W.W. Carley, and G.E. Palade Albumin interacts specifically with a 60-kDa microvascular endothelial glycoprotein Proc Natl Acad Sci U S A 85 1988 6773 6777
33. S.M. Vogel, R.D. Minshall, M. Pillpovic, C. Tiruppathi, and A.B. Malik Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein Am J Physiol Lung Cell Mol Physiol 281 2001 L1512 L1522
34. M.K. Thomsen, V. Diness, P. Nilsson, S.N. Rasmussen, T. Taylor, and U. Hedner Pharmacokinetics of recombinant factor VIIa in the rat. A comparison of bio-, immuno- and isotope assays Thromb Haemost 70 1993 458 464
35. J.D. Termine, H.K. Kleinman, S.W. Whitson, K.M. Conn, M.L. McGarvey, and G.R. Martin Osteonectin, a bone-specific protein linking mineral to collagen Cell 26 1981 99 105
36. J.R. Levick Permeability of rheumatoid and normal human synovium to specific plasma proteins Arthritis Rheum 24 1981 1550 1560
37. A. Wunder, U. Muller-Ladner, E.H. Stelzer, J. Funk, E. Neumann, and G. Stehle et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis J Immunol 170 2003 4793 4801
38. P. Yeh, D. Landais, M. Lemaitre, I. Maury, J.Y. Crenne, and J. Becquart et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate Proc Natl Acad Sci U S A 89 1992 1904 1908
39. F. Kratz Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J Control Release 132 2008 171 183